Latest news with #MICU
Medscape
11 hours ago
- Health
- Medscape
Metabolic Dysbiosis Score Predicts Mortality Risk in ICU
A fecal metabolic dysbiosis score (MDS) predicted 30-day mortality in critically ill patients and may help identify fecal metabolites as a potential treatable trait to improve survival in these patients. METHODOLOGY: Researchers prospectively collected fecal specimens from 196 critically ill patients (median age, 64 years; about half men) admitted to the medical intensive care unit (MICU) for non-COVID-19 respiratory failure or shock. They analyzed the specimens, defined microbiome compositions by shotgun metagenomic sequencing, and quantified microbiota-derived fecal metabolites by mass spectrometry. They then correlated microbiota features and metabolites with 30-day mortality. TAKEAWAY: Overall, 30-day mortality was 30.6%. There was no significant difference between survivors and nonsurvivors regarding age, sex, race, and comorbidity burden. Microbiota compositions of the first fecal sample after MICU admission did not independently associate with 30-day mortality, nor were there associations between single metabolites and 30-day mortality. However, by integrating the fecal metabolite concentrations of 13 microbiota-derived metabolites, the team developed an MDS that predicted 30-day mortality independent of known confounders. The MDS may complement existing tools to identify patients at high risk for mortality by incorporating potentially modifiable, microbiome-related, independent contributors to host resilience. IN PRACTICE: 'Fecal metabolic dysbiosis, determined by quantitation of 13 fecal metabolites, is independently associated with 30-day mortality after MICU admission in our cohort,' the study authors wrote. 'Therefore, fecal metabolic dysbiosis represents a potentially treatable trait to improve survival in heterogeneous critically ill patients,' and the MDS may serve as a biomarker to identify patients who might benefit from such treatment. SOURCE: The study was led by Alexander P. de Porto, PhD, University of Chicago, Chicago, and was published online in Science Advances . LIMITATIONS: The study had limitations. Patients were recruited at a single tertiary academic center and needed respiratory support or a vasopressor, and thus, the results might not be representative of the entire medical ICU population. Also, patients who did not produce a fecal sample or gave a sample that was not analyzable for metagenomics and metabolomics were excluded. DISCLOSURES: The study was funded by the Duchossois Family Institute. de Porto was funded by the Niels Stensen Fellowship. The Center for Research Informatics is funded by the Biological Sciences Division at the University of Chicago, with additional funding provided by the Institute for Translational Medicine and the National Institutes of Health (NIH). One co-author was funded by the NIH/National Heart, Lung, and Blood Institute. The authors declared having no competing interests.
The Hindu
08-06-2025
- Health
- The Hindu
PIMS launches state-of-the-art MICU, biological therapy for asthma patients
The Pondicherry Institute of Medical Sciences (PIMS) recently launched a state-of-the-art Medical ICU and introduced a new biological therapy for asthma patients. The MICU was launched at an event by K. Jacob, PIMS chairman and Susan Thomas, treasurer. The ceremony was attended Renu G'Boy, Director, Peter Manoharan, Medical Superintendent, Achu Jacob Philip, DMS Emergency care and ICU, and Nayyar Iqbal, coordinator, medical education, senior consultants and staff. According to a press release, the 11-bedded MICU has a host of advanced facilities, including advanced hemodynamic monitoring, dialysis equipment and other point-of-care diagnostics. In a first, PIMS has introduced administering of Benralizumab, a state-of-the-art biological therapy, for patients suffering from severe eosinophilic asthma, the press release said. Benralizumab is a monoclonal antibody that works by depleting eosinophils – a type of white blood cell involved in the inflammation seen in certain types of asthma – and has been approved globally for patients who remain symptomatic despite high-dose inhaled corticosteroids and other controller therapies. According to Antonious Maria Selvam, Head of the Department of Respiratory Medicine at PIMS, the cutting edge modality with Benralizumab offers a targeted approach that can dramatically improve the lives of patients with severe eosinophilic asthma, especially those who have long struggled with uncontrolled symptoms despite standard treatments. 'By reducing exacerbations and hospitalisations, it enhances overall quality of life and long-term disease control,' Dr. Selvam said. It is proposed to expand access to biologic therapies and offer the best possible outcomes for patients with complex respiratory diseases, he added.
Yahoo
21-05-2025
- Health
- Yahoo
CHKD celebrates 50 years of mobile intensive care units, unveils new transport vehicle
NORFOLK, Va. (WAVY) — Children's Hospital of the King's Daughters on Tuesday celebrated their Mobile Intensive Care Unit being in service for 50 years. 'Each year, our mobile intensive care unit handles about 1,500 calls,' said a CHKD representative. 'Over the 50 years, that something like 50,000 patients.' To mark the 50th anniversary, CHKD unveiled its newest MICU transport vehicle, decorated with colorful artwork provided by Virginia Beach-based artist Troy Summerell, also known as OnieTonie. CHKD's transport vehicles are the only ones in the area permitted to provide neonatal transports, such as the lifesaving ride Laney Lion received when she was just 7-days old. 'Long story short, 911 was called, and the ambulatory unit was called,' said her mom, Stephanie Lion. 'An EMT who is a veteran of 34 years made the call to intubate Laney at an urgent care to do an IO procedure.' She said after speaking with people she knows, she realizing looking back what a lifesaving move it was. 'I have a friend that's been an ER doctor for 30 years saying 'I know what that is in theory, but I've never done one, or I've never intubated an infant,'' she said, recalling what they told her. The MICU arrived at the CHKD Urgent Care in Virginia Beach and rushed Laney to the Norfolk campus. She credits the hard working ambulatory staff for keeping her alive until they got Laney to the hospital. Once they got to CHKD, Stephanie Lion learned her daughter would need an open heart surgery at just two weeks old for congenital heart defects. Nine years later, she's a spunky and fashionable girl with her whole life ahead of her because of a team of heroes. 'The people that I say saved Laney's life are the people that were on that ambulatory unit,' Stephanie Lion said. 'So I just can't thank you enough. It was a miracle of a night. And this is a miracle of the place. And, I couldn't be more grateful.' According to CHKD, two teams are in place 24/7 to transport acute and non-acute pediatric patients. Each team consists of a specially trained intensive care registered nurse, paramedic and respiratory therapist, all qualified in to care for newborns to teenagers. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
